PHIO · XBRL financial data

Phio Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PHIO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	1,808	1,007*	1,148	866	644	985*	886	1,074	1,181	1,477*	2,793	3,082
General and administrative	968	766*	1,061	1,048	946	689*	986	1,235	1,324	1,057*	1,374	1,186
Total operating expenses	2,776	1,899*	2,209	1,914	1,590	1,674*	1,872	2,309	2,505	2,534*	4,167	4,268
Operating income (loss)	(2,776)	(1,899)*	(2,209)	(1,914)	(1,590)	(1,674)*	(1,872)	(2,309)	(2,505)	(2,534)*	(4,167)	(4,268)
Interest expense	—	—	(53)	—	—	—	(125)	—	—	—	—	—
Other income (expense)	—	—	—	—	0	6*	(22)	0	0	0*	3	0
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(2,780)	(1,895)*	(2,154)	(1,846)	(1,524)	(1,626)*	(1,769)	(2,166)	(2,392)	(2,371)*	(4,003)	(4,138)
Earnings per share, basic USD per share	(1.14)	—	(0.47)	(3.62)	(1.54)	—	(0.41)	(0.45)	(0.44)	—	(0.34)	(0.36)
Earnings per share, diluted USD per share	(1.14)	—	(0.47)	(3.62)	(1.54)	—	(0.41)	(0.45)	—	—	—	—
Weighted average shares, basic thousands of shares	2,440	—	4,580	510	990	—	4,307	4,795	5,469	—	11,617	11,617
Weighted average shares, diluted thousands of shares	2,440	—	4,580	510	990	—	4,307	4,795	—	—	—	—

Fiscal quarters (PHIO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	8,407	8,490	6,475	4,698	5,390	5,382	13,278	10,775	10,705	21,031	17,031	12,996
Prepaid and other current assets	871	832	373	594	474	354	158	519	788	445	371	1,302
Total current assets	9,328	9,322	6,848	5,292	5,864	5,736	13,436	11,294	11,493	21,476	17,402	14,298
Property and equipment, net	142	6	2	1	1	2	4	7	12	11	10	9
Right-of-use asset	66	33	0	0	0	0	—	—	—	—	—	—
Total assets	9,539	9,364	6,853	5,296	5,865	5,738	13,440	11,301	11,505	21,487	17,412	14,307
Accounts payable	173	657	320	335	184	253	427	235	516	435	260	901
Accrued liabilities	2,083	942	929	1,188	735	762	843	971	1,150	905	690	804
Total current liabilities	2,326	1,634	1,249	1,523	919	1,015	1,270	1,206	—	—	—	—
Lease liability, non-current	0	0	—	—	—	0	—	—	—	—	—	—
Total liabilities	2,326	1,634	—	—	—	1,015	1,270	1,206	1,666	1,340	950	1,705
Accumulated deficit	(137,311)	(139,206)	(141,360)	(143,206)	(144,730)	(146,356)	(148,125)	(150,291)	(152,683)	(155,054)	(159,057)	(163,195)
Total stockholders' equity	7,213	7,730	5,604	3,773	4,946	4,723	12,170	10,095	9,839	20,147	16,462	12,602
Total liabilities and equity	9,539	9,364	6,853	5,296	5,865	5,738	13,440	11,301	11,505	21,487	17,412	14,307
Common shares outstanding (cover page) thousands of shares	2,443	4,592	4,592	861	1,055	4,778	4,798	5,727	10,764	11,617	11,617	11,617

Fiscal quarters (PHIO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(2,780)	(1,895)*	(2,154)	(1,846)	(1,524)	(1,626)*	(1,769)	(2,166)	(2,392)	(2,371)*	(4,003)	(4,138)
Stock-based compensation	89	9*	32	15	52	48*	43	51	113*	274*	318	278*
Depreciation and amortization	15*	10*	1	1*	0*	0*	0	0*	2*	1*	1	1*
Net cash from operating activities	(2,900)*	(2,370)*	(2,011)	(1,777)*	(1,953)*	(1,371)*	(1,275)	(2,540)*	(2,085)*	(2,079)*	(4,003)	(4,035)*
Purchases of property and equipment	0*	0*	0	0*	0*	1*	2	3*	7*	0*	0	0*
Net cash from investing activities	0*	0*	0	0*	0*	8*	(2)	(3)*	(7)*	0*	3	0*
Proceeds from issuing equity	—	2,404*	—	—	—	1,356*	—	—	—	year only	—	—
Net cash from financing activities	0*	2,403*	(4)	0*	2,645*	1,355*	9,173	40*	2,022*	12,405*	0	0*
Net change in cash	—	—	—	—	—	(8)*	7,896	(2,503)*	(70)*	10,326*	(4,000)	(4,035)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Phio Pharmaceuticals	12,996	not reported	(4,035)*	11.6M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Palisade Bio	125,172	500	(7,603)*	174.3M	16.5 quarters	Q2 FY26 10-QJun 30, 2026
Citius Pharmaceuticals	17,008	1,494	(8,678)*	27.5M	2.0 quarters	Q3 FY26 10-QJun 30, 2026
Cocrystal Pharma	2,169	105	(2,516)*	19.3M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Brainstorm Cell Therapeutics	22	not reported	(895)	11.0M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Kiora Pharmaceuticals	7,077	not reported	(1,892)*	4.4M	8.9 quarters	Q2 FY26 10-QJun 30, 2026
Cypherpunk Technologies	7,624	not reported	(2,692)*	107.8M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Scienture Holdings	8,188	344	(3,132)*	41.1M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
LeonaBio	32,323	not reported	(16,958)*	9.4M	3.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.